Related Experiment Video
Updated: May 6, 2026

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
Published on: July 25, 2013
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Xiong Xie1,2, Qiaoshuai Lan3, Jinyi Zhao2,4
1Drug Discovery and Design Center, State Key Laboratory of Drug Research, CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
Abstract:
Respiratory disease caused by coronavirus infection remains a global health crisis. Although several SARS-CoV-2-specific vaccines and direct-acting antivirals are available, their efficacy on emerging coronaviruses in the future, including SARS-CoV-2 variants, might be compromised. Host-targeting antivirals provide preventive and therapeutic strategies to overcome resistance and manage future outbreak of emerging coronaviruses. Cathepsin L (CTSL) and calpain-1 (CAPN1) are host cysteine proteases which play crucial roles in coronaviral entrance into cells and infection-related immune response. Here, two peptidomimetic α-ketoamide compounds, 14a and 14b, were identified as potent dual target inhibitors against CTSL and CAPN1. The X-ray crystal structures of human CTSL and CAPN1 in complex with 14a and 14b revealed the covalent binding of α-ketoamide groups of 14a and 14b to C25 of CTSL and C115 of CAPN1. Both showed potent and broad-spectrum anticoronaviral activities in vitro, and it is worth noting that they exhibited low nanomolar potency against SARS-CoV-2 and its variants of concern (VOCs) with EC50 values ranging from 0.80 to 161.7 nM in various cells. Preliminary mechanistic exploration indicated that they exhibited anticoronaviral activity through blocking viral entrance. Moreover, 14a and 14b exhibited good oral pharmacokinetic properties in mice, rats and dogs, and favorable safety in mice. In addition, both 14a and 14b treatments demonstrated potent antiviral potency against SARS-CoV-2 XBB 1.16 variant infection in a K18-hACE2 transgenic mouse model. And 14b also showed effective antiviral activity against HCoV-OC43 infection in a mouse model with a final survival rate of 60%. Further evaluation showed that 14a and 14b exhibited excellent anti-inflammatory effects in Raw 264.7 mouse macrophages and in mice with acute pneumonia. Taken together, these results suggested that 14a and 14b are promising drug candidates, providing novel insight into developing pan-coronavirus inhibitors with antiviral and anti-inflammatory properties.
Insights
Two novel compounds, 14a and 14b, effectively inhibit host proteases Cathepsin L and calpain-1, demonstrating broad-spectrum antiviral activity against SARS-CoV-2 variants and HCoV-OC43, with promising anti-inflammatory effects.
Area of Science:
- Virology
- Drug Discovery
- Immunology
Background:
- Emerging coronaviruses pose a global health threat, necessitating novel therapeutic strategies beyond existing vaccines and antivirals.
- Host-targeting antivirals offer a promising approach to combat viral resistance and future outbreaks.
- Cathepsin L (CTSL) and calpain-1 (CAPN1) are critical host proteases involved in coronavirus entry and immune responses.
Purpose of the Study:
- To identify and characterize novel dual inhibitors targeting CTSL and CAPN1 for broad-spectrum coronavirus treatment.
- To evaluate the in vitro and in vivo antiviral efficacy and safety of these inhibitors against SARS-CoV-2 and other coronaviruses.
- To assess the anti-inflammatory properties of the identified compounds.
Main Methods:
- Identification of peptidomimetic α-ketoamide compounds (14a and 14b) as dual CTSL and CAPN1 inhibitors.
- X-ray crystallography to elucidate the binding mechanism of compounds with CTSL and CAPN1.
- In vitro antiviral assays against SARS-CoV-2 and its variants, and HCoV-OC43.
- In vivo studies in mouse models to assess pharmacokinetic properties, safety, antiviral efficacy, and anti-inflammatory effects.
Main Results:
- Compounds 14a and 14b potently inhibited CTSL and CAPN1, with X-ray structures confirming covalent binding.
- Both compounds demonstrated broad-spectrum in vitro antiviral activity, including low nanomolar potency against SARS-CoV-2 and its variants (VOCs).
- In vivo studies showed favorable oral pharmacokinetics, good safety profiles, potent antiviral activity against SARS-CoV-2 XBB 1.16 and HCoV-OC43, and significant anti-inflammatory effects.
Conclusions:
- Compounds 14a and 14b are potent dual inhibitors of CTSL and CAPN1 with broad-spectrum antiviral and anti-inflammatory properties.
- These compounds represent promising drug candidates for developing pan-coronavirus inhibitors.
- The findings offer novel insights into host-targeting strategies for managing current and future coronavirus threats.
More Related Videos
Related Concept Videos
Caspases
Inhibitors of Gram-positive Cell Wall Synthesis
Inhibitors of Bacterial Protein Synthesis
Inhibitors of Viral Protein Synthesis
Anthelminthic Agents

